We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines.
- Authors
Naranbhai, Vivek; Garcia-Beltran, Wilfredo F; Chang, Christina C; Mairena, Cristhian Berrios; Thierauf, Julia C; Kirkpatrick, Grace; Onozato, Maristela L; Cheng, Ju; Denis, Kerri J St; Lam, Evan C; Kaseke, Clarety; Tano-Menka, Rhoda; Yang, Diane; Pavlovic, Maia; Yang, Wendy; Kui, Alexander; Miller, Tyler E; Astudillo, Michael G; Cahill, Jennifer E; Dighe, Anand S
- Abstract
<bold>Background: </bold>Understanding immunogenicity and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is critical to guide rational use.<bold>Methods: </bold>We compared the immunogenicity of mRNA-1273, BNT-162b2, and Ad26.COV2.S in healthy ambulatory adults. We performed an inverse-variance meta-analysis of population-level effectiveness from public health reports in > 40 million individuals.<bold>Results: </bold>A single dose of either mRNA vaccine yielded comparable antibody and neutralization titers to convalescent individuals. Ad26.COV2.S yielded lower antibody concentrations and frequently undetectable neutralization titers. Bulk and cytotoxic T-cell responses were higher in mRNA1273 and BNT162b2 than Ad26.COV2.S recipients. Regardless of vaccine, <50% of vaccinees demonstrated CD8+ T-cell responses. Antibody concentrations and neutralization titers increased comparably after the first dose of either vaccine, and further in recipients of a second dose. Prior infection was associated with high antibody concentrations and neutralization even after a single dose and regardless of vaccine. Neutralization of Beta, Gamma, and Delta strains were poorer regardless of vaccine. In meta-analysis, relative to mRNA1273 the effectiveness of BNT162b2 was lower against infection and hospitalization, and Ad26COV2.S was lower against infection, hospitalization, and death.<bold>Conclusions: </bold>Variation in the immunogenicity correlates with variable effectiveness of the 3 vaccines deployed in the United States.
- Publication
Journal of Infectious Diseases, 2022, Vol 225, Issue 7, p1141
- ISSN
0022-1899
- Publication type
Journal Article
- DOI
10.1093/infdis/jiab593